What is GLP-1 microdosing?

Microdosing means taking a GLP-1 medication at a dose below the lowest FDA-approved starting dose — often described as roughly a quarter of it, though no official definition exists. For semaglutide that can mean as little as 0.05 to 0.25 mg weekly, against an approved starting dose of about 0.25 mg that titrates up to 2.4 mg for weight management. Because the term is not regulated, one seller's microdose is not necessarily the same amount as another's.

Does microdosing a GLP-1 work?

Nobody knows, and that is the accurate answer rather than a hedge. No randomised trial has tested a sub-approved dose, so there is no efficacy figure to quote. Physicians who discuss it describe modest weight loss in the region of 5 to 6 percent, against 15 to 20 percent at approved doses. Absence of evidence is not proof it fails — but it is not evidence that it works either, and it is currently marketed as though the question were settled.

Does microdosing have fewer side effects?

Probably, on the logic of the drug — GLP-1 side effects are dose-related, which is why every approved product is titrated upward slowly. But it has never been measured at these doses: there is no adverse-event table, no discontinuation rate and no placebo comparison for a microdose. The same reasoning that predicts fewer side effects also predicts less effect, and only one half of that trade tends to get quoted.

Is microdosing a GLP-1 safe?

The dose itself is unlikely to be the risk. The risks come from how microdoses are usually obtained: compounded products that are not FDA-reviewed for identity, purity or strength; prescribing relationships that may skip the safety screening standard prescribing applies; and self-measured fractional doses, where you cannot be certain how much you actually took. The American Association of Clinical Endocrinology does not support routine microdosing and recommends approved dosing.

What dose counts as a microdose?

There is no agreed figure, which is itself worth knowing before buying one. The term is applied to anything below the approved starting dose, and providers set their own definitions. If you are being sold a microdose, the useful question is what the actual milligram amount is and how it compares to the approved starting dose of that specific product — not whether the word is being used.

Is microdosing cheaper than a normal GLP-1 dose?

Not necessarily, and often not. A microdose tier sold by a telehealth provider is priced as a programme rather than by the milligram, so less medication does not translate into a lower bill. At least one microdose tier in our directory costs more per month than the cheapest published price for a full-dose FDA-approved GLP-1.

Which GLP-1 is best for microdosing?

No comparison exists, because no trial has tested any GLP-1 at these doses, let alone compared them. Most microdose products are compounded semaglutide, which reflects what compounding pharmacies supply rather than any finding that semaglutide is better suited to it.

GLP-1 Microdosing: What the Evidence Actually Shows

Direct answer

What you need to know

Evidence strength: Not established

No randomised clinical trial has tested microdosing GLP-1 medications. The term means taking one at a fraction of the FDA-approved starting dose — commonly cited as roughly 25% — though no official definition exists. The American Association of Clinical Endocrinology explicitly does not support it as routine care. Claims about weight management, energy, inflammation or longevity at these doses are extrapolated from studies of full, approved doses.

Key takeaways

Zero randomised trials at these dose levels. Not weak evidence — absent evidence.
A professional body has taken an explicit position against it as routine care.
Physicians quoted on the subject describe modest results, around 5–6%, against 15–20% at approved doses.
There is one partial exception worth knowing about, at the lowest approved dose — which is a different thing from microdosing.

Important limitation: Absence of evidence is not evidence of absence: nobody has shown microdosingfails either. What can be said is that anyone quoting a benefit at these doses is extrapolating, and that the extrapolation has not been tested.

Next action: If you are considering it regardless, the distinction that actually changes your risk is whether a prescriber is involved — how it is done in practice sets out why.

Primary sources: FDA, DailyMed — FDA labels

General education, not medical advice, and not an endorsement of microdosing.

What “microdosing” actually means

There is no FDA-recognised microdose. The term describes doses below the lowest approved starting dose — sometimes as little as 0.05–0.25 mg of semaglutide weekly, against an approved starting dose of roughly 0.25 mg building toward a 2.4 mg maintenance dose for weight management. Wellness and telehealth companies define “microdose” arbitrarily, and definitions vary between providers — a “microdose” from one seller is not necessarily the same amount as from another.

What the evidence actually shows

This is the honest, unglamorous answer: we don’t have evidence that low-dose, intermittent use of GLP-1s provides meaningful or sustained weight loss. The trials that established these drugs work — the ones behind every figure on this site — tested the FDA-approved dose ranges, not fractional doses. Physicians quoted on the subject describe weight loss at very low doses as modest, in the region of 5–6%, compared with 15–20% at approved doses.

One partial exception: real-world data on the lowest approved semaglutide dose (1 mg, used for diabetes) found weight loss not far off the 2.4 mg weight-management dose in that specific comparison — a genuinely interesting finding that more is not always proportionally better within the approved range. That is a different question from microdosing below approved doses entirely, and it does not extend to the much lower amounts marketed as “microdoses.”

Absence of evidence is not evidence that it doesn’t work — but it is not evidence that it does, either. Right now, microdosing is an open question being marketed as a settled one.

Claims about anti-inflammatory, cardioprotective, or longevity benefits at microdose levels are, at this point, extrapolation from research on full-dose GLP-1 effects — not findings specific to very low doses. That may change as research continues; it is not where the evidence stands today.

The anti-inflammatory claim is the one that travels furthest, usually attached to an autoimmune condition, so it is worth knowing how much is being extrapolated from. Even at full approved doses the picture is thin and uneven: real randomised trials in plaque psoriasis, observational data only in inflammatory bowel disease, laboratory work alone in rheumatoid arthritis. We set out the evidence behind the inflammation claim, condition by condition. A microdose claim inherits every weakness in that research and then adds the assumption that a quarter of the dose does the same thing.

Why a professional body has taken a position on this

The American Association of Clinical Endocrinology does not support routine microdosing of GLP-1 receptor agonists in clinical care, and recommends adherence to FDA-approved dosing. That is a notably direct position for a professional society to take, and reflects that the practice is happening in the market well ahead of any evidence base for it.

The specific risks worth knowing

Compounded microdose products lack FDA testing rigor and may have inconsistent actual dosing from batch to batch — the FDA has reported dosing errors with compounded GLP-1 products causing fainting and severe symptoms.
Because a microdose is usually accessed outside a full prescribing relationship for an approved indication, the same safety screening (thyroid history, pancreatitis history, pregnancy status) that applies to standard prescribing may not be applied as rigorously.
Self-directed dose-splitting or measuring — drawing a fraction of an injector-pen dose yourself — introduces real measurement error on a drug where the margin between doses matters.

Do microdoses have fewer side effects?

This is the most common reason people give for wanting one, and it deserves a careful answer rather than a reassuring one. The expectation is reasonable, and it has never been measured at these doses.

The reasoning behind it is sound as far as it goes. GLP-1 side effects are dose-related: the approved labels show nausea and the rest flaring after each dose increase and settling again, which is why every product is titrated upward slowly instead of started at the maintenance dose. A smaller dose should, on that logic, produce less of them. Nothing in the evidence contradicts that.

What does not follow is that anyone has checked. No trial has tested a sub-approved dose, so there is no adverse-event table for a microdose, no discontinuation rate, and no placebo arm to read them against — the figures on our side-effects pages all come from trials of approved doses, and none of them transfers. The same reasoning that predicts fewer side effects predicts less effect, and only one half of that trade tends to get quoted.

There is also a risk specific to microdosing rather than inherited from the drug. If the product is compounded and the dose is measured by drawing part of a pen or vial yourself, then the amount you receive is uncertain in a way an approved pen’s is not. In that situation “fewer side effects at a lower dose” assumes you know what dose you took, which is the assumption the whole practice rests on and the one nobody verifies.

What is actually being sold as a microdose

It is worth grounding this in something specific, because the word gets used loosely. Microdosing is not only a self-directed practice — it is a commercial product tier. At least one provider in our directory sells one under that name: Noom Med publishes a Microdose tier at $79 to start and $179 a month with the medication included, verified on our last sweep.

Two things follow from that. The first is that a microdose bought this way is a compounded preparation, not an approved product, so the regulatory position is the compounding one rather than anything specific to the dose. The second is a matter of arithmetic that the marketing does not present. At $179 a month it costs more than the cheapest published price for an FDA-approved GLP-1, which is $149. A smaller dose is not automatically a cheaper one.

If you’re considering it anyway

The single most important distinction is supervised versus unsupervised use. Microdosing under the guidance of a prescriber who knows your history and is monitoring you is a different risk profile from self-directed use of a compounded product bought online. Practical, prescriber-supervised considerations are covered in our guide to how microdosing is actually done — which is not an endorsement, but an honest description of the practice for people who are going to encounter it either way.

Common questions

What is GLP-1 microdosing?: Microdosing means taking a GLP-1 medication at a dose below the lowest FDA-approved starting dose — often described as roughly a quarter of it, though no official definition exists. For semaglutide that can mean as little as 0.05 to 0.25 mg weekly, against an approved starting dose of about 0.25 mg that titrates up to 2.4 mg for weight management. Because the term is not regulated, one seller's microdose is not necessarily the same amount as another's.
Does microdosing a GLP-1 work?: Nobody knows, and that is the accurate answer rather than a hedge. No randomised trial has tested a sub-approved dose, so there is no efficacy figure to quote. Physicians who discuss it describe modest weight loss in the region of 5 to 6 percent, against 15 to 20 percent at approved doses. Absence of evidence is not proof it fails — but it is not evidence that it works either, and it is currently marketed as though the question were settled.
Does microdosing have fewer side effects?: Probably, on the logic of the drug — GLP-1 side effects are dose-related, which is why every approved product is titrated upward slowly. But it has never been measured at these doses: there is no adverse-event table, no discontinuation rate and no placebo comparison for a microdose. The same reasoning that predicts fewer side effects also predicts less effect, and only one half of that trade tends to get quoted.
Is microdosing a GLP-1 safe?: The dose itself is unlikely to be the risk. The risks come from how microdoses are usually obtained: compounded products that are not FDA-reviewed for identity, purity or strength; prescribing relationships that may skip the safety screening standard prescribing applies; and self-measured fractional doses, where you cannot be certain how much you actually took. The American Association of Clinical Endocrinology does not support routine microdosing and recommends approved dosing.
What dose counts as a microdose?: There is no agreed figure, which is itself worth knowing before buying one. The term is applied to anything below the approved starting dose, and providers set their own definitions. If you are being sold a microdose, the useful question is what the actual milligram amount is and how it compares to the approved starting dose of that specific product — not whether the word is being used.
Is microdosing cheaper than a normal GLP-1 dose?: Not necessarily, and often not. A microdose tier sold by a telehealth provider is priced as a programme rather than by the milligram, so less medication does not translate into a lower bill. At least one microdose tier in our directory costs more per month than the cheapest published price for a full-dose FDA-approved GLP-1.
Which GLP-1 is best for microdosing?: No comparison exists, because no trial has tested any GLP-1 at these doses, let alone compared them. Most microdose products are compounded semaglutide, which reflects what compounding pharmacies supply rather than any finding that semaglutide is better suited to it.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

Can microdosing GLP-1s promote health and weight loss?Cedars-Sinai (expert commentary)Supports: The absence of evidence for meaningful weight loss at microdose levels, and the specific risks named by physicians quoted.
AACE clinical practice position on GLP-1 receptor agonist dosingAmerican Association of Clinical EndocrinologySupports: AACE's position that routine microdosing is not supported and that FDA-approved dosing should be followed.
Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: FDA reports of dosing errors with compounded GLP-1 products.
FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The FDA-approved dose ranges that microdosing falls below.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.

GLP-1 microdosing: what the evidence actually shows